Life science news 21 September 2026: first US Sanfilippo approval, DESTINY-Lung04 data and a NICE OCD consultation.
The FDA approved Fayuvi, the first treatment for Sanfilippo syndrome type A. AstraZeneca and Daiichi Sankyo’s Enhertu cut the risk of lung cancer progression by 37% against standard care. NICE proposed earlier assessment for OCD and body dysmorphic disorder, including in cosmetic settings.
The FDA approved Fayuvi (rebisufligene etisparvovec-hopf) on 17 September 2026. The FDA describes it as the first treatment for children with Sanfilippo syndrome type A, also known as MPS IIIA. It is a one-time intravenous AAV9 gene therapy that delivers a working copy of the SGSH gene. Ultragenyx said the FDA granted standard full approval. The indication covers neurologic manifestations of MPS IIIA in paediatric patients with preserved neurodevelopmental function. The ultra-rare, fatal lysosomal storage disorder causes progressive loss of cognitive, language and motor function in childhood. The approval follows a 2025 FDA complete response letter that cited manufacturing. Ultragenyx’s chief commercial officer said the US wholesale acquisition cost will be US$3.95 million. Fayuvi is the company’s second gene therapy approval, after Genglycos in August.
The approval rests on the single-arm, open-label Transpher A study and long-term follow-up. Seventeen treated children were compared with 27 untreated patients from an external natural history cohort. Treated children scored 23.5 points higher on the Bayley-III cognitive scale (p<0.0001). Assessments covered ages 24 to 60 months. Emil D. Kakkis, chief executive officer and president of Ultragenyx, cited “unwavering support from so many families and patient organizations.” Kevin M. Flanigan directs the Center for Gene Therapy at Nationwide Children’s Hospital and was principal investigator. He called Fayuvi “a promising therapeutic option.” The label carries warnings for hepatotoxicity, thrombocytopenia and thrombotic microangiopathy. It also warns of a potential malignancy risk from vector integration. All patients receive corticosteroids from the day before infusion for at least eight weeks.
AstraZeneca and Daiichi Sankyo reported full DESTINY-Lung04 results on 14 September 2026. The Phase III trial tested Enhertu against pembrolizumab plus platinum-pemetrexed chemotherapy. Patients had untreated, HER2-mutant, advanced non-squamous non-small cell lung cancer. Enhertu cut the risk of disease progression or death by 37% (hazard ratio 0.63). Progression-free survival was the primary endpoint, assessed by blinded independent central review. Median progression-free survival was 14.3 months on Enhertu and 8.3 months on the comparator. Objective response rate was 70.0% against 44.5%. Susan Galbraith is Executive Vice President, Oncology Haematology R&D at AstraZeneca. She described it as “the first Phase III trial to demonstrate superior progression-free survival” against first-line standard of care.
John Tsai is global head of R&D at Daiichi Sankyo. He said the results “reinforce the importance of targeting HER2 directly in these patients.” Overall survival data were 46.9% mature, and no formal hypothesis testing was performed. Median overall survival was 29.3 months on Enhertu and 33.1 months on the comparator (hazard ratio 1.15). The companies said imbalanced subsequent therapy between arms may limit interpretation of the survival data. Enhertu carries a US boxed warning for interstitial lung disease and embryo-foetal toxicity. Adjudicated interstitial lung disease or pneumonitis occurred in 20.8% of Enhertu-treated patients. Most cases were Grade 1 or 2, but four were fatal (Grade 5, 1.8%).
NICE published draft guidance on 17 September 2026 to improve identification of obsessive-compulsive disorder (OCD) and body dysmorphic disorder (BDD). The draft advises healthcare professionals to consider assessing for OCD or BDD in people with depression, anxiety, autism or ADHD. It gives the same advice for people seeking cosmetic procedures. Cosmetic practitioners, including surgeons, dentists and dermatologists, would ask structured questions about appearance concerns. If responses suggest BDD, the draft recommends specialist referral rather than proceeding with the procedure at that stage. NICE is also proposing a “matched care” approach to OCD treatment. This tailors treatment to individual needs rather than a fixed stepped pathway. Family-based cognitive behavioural therapy is recommended for many children and young people with OCD.
Eric Power is interim director of NICE’s Centre for Guidelines. He said: “Earlier identification can help ensure people receive care that reflects their needs, preferences and circumstances.” The draft updates NICE’s 2005 guideline on OCD and BDD, which covers adults, children and young people. The consultation runs until 21 October 2026. This is a consultation draft, and the announcement did not give a date for final guidance. NICE guidelines apply in England. No cost-effectiveness or NHS budget impact figures were included in the announcement.
Novo Nordisk and Orbis Medicines announced a drug discovery partnership on 17 September 2026. Novo Nordisk now trades day to day as Novo, following a rebrand on 14 September. Novo Nordisk A/S remains its legal name. The deal is worth up to US$1.4 billion in upfront and milestone payments, plus tiered royalties. It covers orally bioavailable macrocycles, which Orbis says have the potential to replace injectable medicines. Orbis will apply its nGen platform, which combines generative AI with high-throughput synthesis. The work will focus on undisclosed cardiometabolic targets. Novo Nordisk will also make a strategic investment in Orbis. Neither the investment amount nor the upfront payment was disclosed.
Morten Graugaard is chief executive officer of Orbis Medicines. He said the future of oral biologic drug discovery lies at the intersection of AI and proprietary macrocycle data. Brian Vandahl is senior vice president, Therapeutics Discovery, at Novo Nordisk. He said the collaboration could “unlock innovative oral treatment options for patients with cardiometabolic diseases.” The programmes are at the discovery stage, and no candidates are in clinical trials. Orbis is eligible for development and commercial milestones, plus tiered royalties on future product sales.
In further life science news 21 September 2026, Roche agreed a US$1 billion bispecific antibody deal. Other highlights include a Parkinson’s licence and early in vivo CAR-T and radiotherapy data.
Roche agreed a bispecific antibody research collaboration with Dualitas Therapeutics on 17 September 2026. The deal is worth up to US$1 billion, including US$36.5 million upfront. Dualitas will use its DualScreen platform to screen more than 300,000 bispecific combinations. The platform screens for what the company calls proximity biology across cell surface targets. The work covers immunology and inflammation diseases. Roche will lead all later preclinical, regulatory, manufacturing and commercial work. Dualitas has three internal development candidates: DTX-101, DTX-102 and DTX-103. Co-founder Forbes Huang said its pipeline is entering the clinic next year.
Karim Dabbagh is chief executive officer of Dualitas. He said Dualitas’ technologies could identify bispecific antibodies that “harness novel proximity mechanisms.” Boris L. Zaïtra is head of corporate business development at Roche. He said: “Bispecific antibodies remain central to Roche’s portfolio strategy across many disease areas.” Dualitas is eligible for research, development and commercial milestones, plus tiered royalties. The collaboration is at the discovery and screening stage. No clinical candidates have yet been identified under the agreement.
SK Biopharmaceuticals licensed a Parkinson’s disease drug candidate from 1ST Biotherapeutics on 17 September 2026. The deal covers 1ST-104. It is an oral small-molecule dual LRRK2 and c-Abl kinase inhibitor, still in preclinical development. SK Biopharmaceuticals will pay US$1.8 million upfront. The total could reach US$314.8 million, including a US$1.8 million near-term milestone on candidate selection. Tiered royalties would apply to future sales. SK Biopharmaceuticals is also making a US$2.2 million strategic equity investment in 1ST Biotherapeutics. It gains exclusive worldwide rights to develop and commercialise the candidate.
Donghoon Lee is chief executive officer of SK Biopharmaceuticals. He said the deal “combines 1ST Biotherapeutics’ early-stage discovery capabilities with SK Biopharmaceuticals’ clinical development and commercialization expertise.” 1ST Biotherapeutics says 1ST-104 has shown target selectivity and blood-brain barrier permeability in preclinical studies. The candidate has not yet entered human clinical trials. No efficacy or safety data in people have been disclosed.
Tempest Therapeutics secured an exclusive option to license a cell therapy platform on 15 September 2026. The CD7-targeted lentiviral platform comes from Hebei Senlang Biotechnology. It delivers CAR genes directly to CD7-positive T cells and natural killer cells inside the body. This aims to generate CAR-T and CAR-NK cells without collecting or manufacturing cells outside the patient. The lead candidate targets BCMA and GPRC5D and is in Phase 1 dose escalation for relapsed or refractory multiple myeloma. Tempest’s SEC filing puts the option exercise fee at about US$447,000. The licence would cover worldwide rights outside Greater China.
If exercised, annual maintenance fees would rise from US$10 million to US$14 million over three years. Tempest may stop paying them, with corresponding delays to development. A 6% royalty on net sales would also apply. Early data run to 25 August 2026. By then, no Grade 3 or higher cytokine release syndrome had been observed. No immune effector cell-associated neurotoxicity syndrome was seen either. Tempest reported CAR-T generation and expansion at the current highest evaluable dose. Matt Angel is president and chief executive officer of Tempest Therapeutics. He called the agreement “an important step in building Tempest as a multi-platform in vivo CAR-T company.” The data come from a small, ongoing dose-escalation study. No response rate data were disclosed.
Nanobiotix reported full results from a Phase 1 trial of JNJ-1900 on 14 September 2026. Patients had inoperable, locoregionally recurrent non-small cell lung cancer suitable for re-irradiation. JNJ-1900, also known as NBTXR3, is a hafnium oxide nanoparticle injected into a tumour and activated by radiotherapy. The University of Texas MD Anderson Cancer Center sponsored the trial. All 24 patients completed treatment. One-year local progression-free survival was 61%, with a median of 13.6 months. One-year overall survival was 70%, with a median of 14.8 months. The study was not randomised.
Saumil Gandhi, a radiation oncologist at MD Anderson, was the study’s principal investigator. He said recurrent disease is “often more radioresistant because it survived radiation the first time.” He added: “These findings warrant evaluation in a randomized trial.” No dose-limiting toxicities were reported. There were no Grade 3 or higher adverse events related to JNJ-1900 or the injection procedure. Radiotherapy-related Grade 3 events occurred in 33% of patients. Two patients (8%) had fatal, Grade 5 radiotherapy-related events. Janssen, part of Johnson & Johnson, licensed global rights to the therapy in 2023. Johnson & Johnson is running larger studies, including a Phase 3 trial in head and neck cancer. Louis Kayitalire, Nanobiotix’s chief medical officer, said conditions in earlier settings could be “even more favorable.”
That’s your life science news digest for 21 September 2026, back next Monday with the latest from pharma, biotech and healthcare at www.lifesciencedaily.news.
Catch up on the 14 September news roundup.












